Triaryimethanes, a new class of Cx50 inhibitors

Frontiers in Pharmacology

Volumn 3 JUN, Issue , 2012, Pages

  Bodendiek, Silke B ^a   Rubinos, Clio ^b   Trelles, Maria Pilar ^b   Coleman, Nichole ^a   Jenkins, David Paul ^a   Wulff, Heike ^a   Srinivas, Midutur ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Channel; Connexin 50; Gap junctions; Inhibitors; Lens; Pharmacophore; SAR; Triarylmethane

Indexed keywords

1 [(2 CHLOROPHENYL)(DIPHENYL)METHYL] 4 METHYL 2 PHENYL 1H IMIDAZOLE; 1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 2,5 DIHYDRO 1H PYRROLE 2,5 DIONE; 1 [4 [[(2 CHLOROPHENYL)DIPHENYLMETHYL]AMINO]PHENYL]ETHAN 1 ONE; 1 CHLORO 2 (PHENOXYDIPHENYLMETHYL)BENZENE; 2 [[(2 CHLOROPHENYL)DIPHENYLMETHYL]SULFANYL]PYRIMIDINE; CALCIUM CHANNEL; CALCIUM CHANNEL KCA3.1; CLOTRIMAZOLE; CONNEXIN 50; DIPHENYL[2 (TRIFLUOROMETHOXY)PHENYL]METHANOL; GAP JUNCTION PROTEIN; N [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1,3 BENZOTHIAZOL 2 AMINE; N [(2 CHLOROPHENYL)DIPHENYLMETHYL] 2 (TRIFLUOROMETHOXY)ANILINE; N [(2 CHLOROPHENYL)DIPHENYLMETHYL] 3 (TRIFLUOROMETHOXY)ANILINE; N [(2 CHLOROPHENYL)DIPHENYLMETHYL] 4 METHOXYANILINE; N [(2 CHLOROPHENYL)DIPHENYLMETHYL] N (3 AMINOPROPIONITRILE)AMINE; N [(2 CHLOROPHENYL)DIPHENYLMETHYL] N (3 AMINOPROPYL)IMIDAZOLEAMINE; N [(2 CHLOROPHENYL)DIPHENYLMETHYL]ANILINE; N [(2 IODOPHENYL)DIPHENYLMETHYL] 1,3 THIAZOL 2 AMINE; N [(2 METHOXYPHENYL)DIPHENYLMETHYL] 1,3 THIAZOL 2 AMINE; N [(2 METHOXYPHENYL)DIPHENYLMETHYL]PYRIMIDIN 2 AMINE; N [(2 METHYLPHENYL)DIPHENYLMETHYL] 1,3 THIAZOL 2 AMINE; N [(2 METHYLPHENYL)DIPHENYLMETHYL] PYRIMIDIN 2 AMINE; N [DIPHENYL[2 (TRIFLUOROMETHOXY)PHENYL]METHYL] 1,3 THIAZOL 2 AMINE; N [DIPHENYL[2 (TRIFLUOROMETHOXY)PHENYL]METHYL]PYRIMIDIN 2 AMINE; POTASSIUM CHANNEL; PROTEIN INHIBITOR; SODIUM CHANNEL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IC 50; LENS; MOUSE; NONHUMAN; PHARMACOPHORE; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION;

EID: 84866165907     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00106     Document Type: Article

References (34)

1. Baeyer, A. (1907). The investigation of derivatives of triphenylcarbinol. First paper. JustusLiebigs Ann. Chem. 354, 152-204.
2. Bartroli, J., Alguero, M., Boncompte, E., and Forn, J. (1992). Synthesis and antifungal activity of a series of difluorotritylimidazoles. Arzneimittdforschung 42, 832-835.
3. Berthoud, V. M., and Beyer, E. C. (2009). Oxidative stress, lens gap junctions, and cataracts. Antioxid. Redox Signal 11,339-353.
4. Bodendiek, S. B., and Raman, G. (2010). Connexin modulators and their potential targets under the magnifying glass. Cur. Med. Chem. 17,4191-4230.
5. Cruikshank, S. J., Hopperstad, M., Younger, M., Connors, B. W., Spray, D. C, and Srinivas, M. (2004). Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc. Natl Acad. Sci. U.S.A. 101, 12364-12369.
6. Dahlbom, R., and Ekstrand, T. (1944). Trityl derivatives of sulfanilamides. Sven Kern. Tidskr. 56, 304-314.
7. Evans, B. E., Rittle, K. E., Bock, M. G., DiPardo, R. M., Freidinger, R. M., Whitter, W. L, Lundell, G. E, Veber, D. E, Anderson, P. S., and Chang, R. S. (1988). Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31,2235-2246.
8. Gomberg, M., and Van Slyke, D. D. (1911). Triphenylmethyl. XX. /. Am. Chem. Soc. 33,531-549.
9. + channels, types Kvl.l, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol. Pharmacol 45, 1227-1234.
10. Horton, D. A., Bourne, G. T., and Smythe, M. L. (2003). The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev. 103, 893-930.
11. Kandouz, M., and Batist, G. (2010). Gap junctions and connexins as therapeutic targets in cancer. Expert Opin. Ther. Targets 14,681-692.
12. Lang, N. N., Myles, R. C, Burton, F. L., Hall, D. P., Chin, Y. Z., Boon, N. A., and Newby, D. E. (2008). The vascular effects of rotigaptide in vivo in man. Biochem. Pharmacol 76,1194-1200.
13. Locovei, S., Scemes, E., Qiu, E, Spray, D. C, and Dahl, G. (2007). Pannexinl is part of the pore forming unit of the P2X(7) receptor death complex. PEBS Lett. 581,483-488.
14. Mathias, R. T., Rae, J. L, and Baldo, G.J. (1997). Physiological properties of the normal lens. Physiol Rev. 77, 21-50.
15. Mathias, R. T., White, T. W., and Gong, X. (2010). Lens gap junctions in growth, differentiation, and home-ostasis. Physiol Rev. 90,179-206.
16. McNaughton-Smith, G. A., Burns, J. E, Stocker, J. W., Rigdon, G. C, Creech, C, Arrington, S., Shelton, T., and de Franceschi, L. (2008). Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. /. Med. Chem. 51,976-982.
17. Misra, B. K., Rao, Y. R., and Maha-patra, S. N. (1983). Friedel-Crafts acylation of some aromatic compounds with 2-isocyanatobenzoyl chloride.Indian]. Chem. Sect. BUB, 1132-1138.
18. Monder, C, Stewart, P. M., Lakshmi, V., Valentino, R., Burt, D., and Edwards, C. R. (1989). Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 125,1046-1053.
19. Nemani, V M., and Binder, D. K. (2005). Emerging role of gap junctions in epilepsy. Histol. Histopathol 20,253-259.
20. Rong, P., Wang, X., Niesman, I., Wu, Y., Benedetti, L. E., Dunia, I., Levy, E., and Gong, X. (2002). Disruption of Gja8 (alpha 8 connexin) in mice leads to microph-thalmia associated with retardation of lens growth and lens fiber maturation. Development 129, 167-174.
21. Salameh, A.,and Dhein.S. (2005). Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochim. Biophys. Acta 1719, 36-58.
22. Sankaranarayanan, A., Raman, G., Busch, C, Schultz, T., Zimin, P. I., Hoyer, J., Kohler, R., and Wulff, H. (2009). Naphtho[l,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75, 281-295.
23. Srinivas, M., Hopperstad, M. G., and Spray, D. C. (2001). Quinine blocks specific gap junction channel subtypes. Proc. Natl Acad. Sci. U.S.A. 98, 10942-10947.
24. Srinivas, M., and Spray, D. C. (2003). Closure of gap junction channels by arylaminobenzoates. Mol Pharmacol 63, 1389-1397.
25. 2+ signaling. /. Neurosci. 26, 1378-1385.
26. Suessbrich, H., Waldegger, S., Lang, E, and Busch, A. E. (1996). Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385, 77-80.
27. Toyama, K., Wulff, H., Chandy, K. G., Azam, P., Raman, G., Saito, T., Fuji-wara, Y, Mattson, D. L., Das, S., Melvin, J. E., Pratt, P. E, Hatoum, O. A., Gutterman, D. D., Harder, D. R., and Miura, H. (2008). The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J. Clin. Invest. 118, 3025-3037.
28. Vessey, J. P., Lalonde, M. R., Mizan, H. A., Welch, N. C, Kelly, M. E., and Barnes, S. (2004). Carbenoxolone inhibition of voltage-gated Ca channels and synaptic transmission in the retina. /. Neurophysiol 92, 1252-1256.
29. Wermuth, C. G. (2004). Selective optimization of side activities: another way for drug discovery. /. Med. Chem. 47. 1303-1314.
30. White, T. W., Gao, Y., Li, L, Sellitto, C, and Srinivas, M. (2007). Optimal lens epithelial cell proliferation is dependent on the connexin isoform providing gap junctional coupling. Invest. Ophthalmol Vis. Sci. 48,5630-5637.
31. White, T. W., Goodenough, D. A., and Paul, D. L. (1998). Targeted ablation of connexin50 in mice results in microphthalmia and zonular pulverulent cataracts. J. Cell. Biol. 143, 815-825.
32. Wulff, H., Gutman, G. A., Cahalan, M. D., and Chandy, K. G. (2001). Deli-nation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel IKCal. J. Biol. Chem. 276, 32040-32045.
33. Wulff, H., Miller, M. J., Haensel, W. Grissmer, S., Cahalan, M. D., and Chandy, K. G. (2000). Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCal: a potential immunosuppressant. Proc. Natl. Acad. Sci. U.S.A. 97, 8151-8156.
34. Zunszain, P. A., Shah, M. M., Miscony, Z., Javadzadeh-Tabatabaie, M., Haylett, D. G., and Ganellin, C. R. (2002). Tritylamino aromatic heterocycles and related carbinols as blockers of Ca2+-activated potassium ion channels underlying neuronal hyperpolarization. Arch. Pharm. 335, 159-166.